ArticleAdvanced biomedical research2023
The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.
Article in Advanced biomedical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Epidermal growth factor receptor inhibitor-related skin toxicities: a review of management and possible preventive and therapeutic approaches for Asian patients by the Japanese Pharmacist-led Oncodermatology Study Team.International journal of clinical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering the prevalence of cetuximab-induced rashes in colorectal cancer patients and its impact on patient's quality of life and treatment, this study aimed at investigating the effect of topical vitamin K1 on the treatment of skin rashes in metastatic colorectal cancer patients treated with cetuximab. Materials and Methods: This randomized, controlled, triple-blind, clinical trial was conducted on 49 metastatic colorectal cancer patients who were candidates for cetuximab treatment and referred to Omid Hospital in Isfahan during 2021-2022. Vitamin K1 cream with a concentration of 0.1% in the intervention group ( Results: During the intervention, skin rash grades in the fourth and eighth weeks with the means of 1.00 ± 0.64 and 0.84 ± 0.55, respectively, were significantly lower in the intervention group, as compared with the control group with the means of 1.42 ± 0.65 and 1.25 ± 0.68, respectively ( Conclusion: Topical vitamin K1 cream had a significant effect on reducing the severity of cetuximab-induced skin rashes over eight weeks of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.